Skip to main content

Vertex taps California startup for $700M gene-editing deal

Vertex has developed cystic fibrosis therapies and is working with other partners on CRISPR-Cas9 systems as well as messenger RNA, or MRNA, therapies with Moderna Inc.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.